Zhi Xiang Golden Ta (688443.SH): Taileqi monoclonal antibody injection adult, severe atopic dermatitis indications for market application accepted for review.

Zhixing Financial News APP News, Zhixiang Jintai (688443.SH) announced that recently, the company submitted a new drug marketing application for the use of Taliquqi Baidankan Injection (GR1802 Injection) in adults with moderate to severe atopic dermatitis to the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) and it has been accepted for review.